An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Frequency Therapeutics (NASDAQ: FREQ) announced that Chief Scientific Officer Dr. Christopher Loose and Vice President Dr. Sanjay Magavi will present at the B. Riley Securities Neuro & Ophthalmology Conference on April 28, 2022, at 3:30 PM ET. The event will showcase the company's advancements in regenerative medicine, particularly in hearing loss treatment. A live webcast of the presentation will be available on Frequency’s website, with a replay post-event. Frequency is pioneering therapeutics aimed at restoring function through innate regenerative potential activation.
Positive
None.
Negative
None.
LEXINGTON, Mass.--(BUSINESS WIRE)--
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose and Vice President of Discovery Biology Dr. Sanjay Magavi will participate in a fireside presentation at the B. Riley Securities’ Neuro & Ophthalmology Conference on April 28, 2022 at 3:30 pm ET.
A live webcast of both the panel and presentation can be accessed on the Investors & Media section of Frequency’s website and a replay will be posted following the event.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore human function – first in hearing loss and then in multiple sclerosis (MS) – by developing therapeutics that activate a person’s innate regenerative potential within the body through the activation of progenitor cells. Frequency’s hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for sensorineural hearing loss. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss.
Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, the Scripps Research Institute and Cambridge Enterprises Limited.
For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.
